Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

PURPOSE: To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). PATIENTS AND METHODS: Patients with previously untreated AML or...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Garcia-Manero, Guillermo, Tambaro, Francesco Paolo, Bekele, Nebiyou B., Yang, Hui, Ravandi, Farhad, Jabbour, Elias, Borthakur, Gautam, Kadia, Tapan M., Konopleva, Marina Y., Faderl, Stefan, Cortes, Jorge E., Brandt, Mark, Hu, Yumin, McCue, Deborah, Newsome, Willie Mae, Pierce, Sherry R., de Lima, Marcos, Kantarjian, Hagop M.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2012
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4879705/
https://ncbi.nlm.nih.gov/pubmed/22585696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.38.3265
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi